Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Motricity Inc. : Motricity and Voltari Announce Completion of Reorganization Transaction

04/09/2013 | 06:45pm US/Eastern
Recommend:
0


April 9, 2013

Motricity and Voltari Announce Completion of Reorganization Transaction

NEW YORK, April 9, 2013 (GLOBE NEWSWIRE) -- Voltari Corporation ("Voltari") and Motricity, Inc. ("Motricity") (Nasdaq:MOTR), today announced the consummation of a Reorganization intended to protect the long-term value of Motricity's substantial net operating loss carryforwards.
Upon completion of the Reorganization, Motricity became a wholly owned subsidiary of Voltari, which replaces Motricity as a publicly held corporation. It is anticipated that, as of April 10, 2013, shares of Voltari Common Stock will commence trading on the NASDAQ Capital Market under the symbol "VLTC."
Pursuant to an Agreement and Plan of Reorganization by and between Motricity, Voltari and Voltari Merger Sub, Inc., adopted by Motricity stockholders at a special meeting held on April 9, 2013, Motricity became a wholly owned subsidiary of Voltari, each outstanding share of common stock of Motricity ("Motricity Common Stock") was converted into the right to receive one share of common stock of Voltari ("Voltari Common Stock"), each outstanding share of preferred stock of Motricity became the right to receive one share of preferred stock of Voltari, each outstanding warrant to purchase shares of Motricity Common Stock became the right to receive a warrant to purchase an equivalent number of shares of Voltari Common Stock, and each option
to purchase shares of Motricity Common Stock was assumed by Voltari and became exercisable for an equivalent number of shares of Voltari Common Stock. Each share of Voltari Common Stock is subject to certain transfer restrictions (that were not applicable to Motricity Common Stock) prohibiting transfers having the effect of increasing the ownership of Voltari Common Stock by (i) any person from less than 5% to 5% or more or (ii) any person owning or deemed to own 5% of more of Voltari's Common Stock.
The directors and executive officers of Voltari immediately following the Reorganization are the same individuals who were directors and executive officers of Motricity immediately prior to the Reorganization.
Upon completion of the Reorganization, Voltari Common Stock was deemed to be registered under Section 12(b) of the
Securities Exchange Act of 1934, as amended, pursuant to Rule 12g-3(a) promulgated thereunder. For purposes of Rule 12-g
3(a), Voltari is the successor issuer to Motricity.

About Voltari

Voltari empowers mobile operators, brands and advertising agencies to maximize the reach and economic potential of the mobile ecosystem through the delivery of relevance-driven merchandising, marketing and advertising solutions. Voltari leverages advanced predictive analytics capabilities to deliver the right content, to the right person at the right time. Voltari provides their entire suite of mobile data service solutions through one, integrated, highly scalable managed service platform. Voltari's unique combination of technology, expertise and go-to-market approach delivers return-on-investment for our mobile operator, brand and advertising agency customers. For more information, visit www.voltari.com or follow @voltari on Twitter.

Safe Harbor and Forward-Looking Statements

Statements made in this report and related statements that express Voltari's or its management's intentions, indications, beliefs, expectations, guidance, estimates, forecasts or predictions of the future constitute forward-looking statements, as defined by the Private Securities Litigation Reform Act of 1995, and relate to matters that are not historical facts. They include, without limitation, statements related to whether and when the Voltari Common Stock will trade on NASDAQ. These statements represent beliefs and expectations only as of the date they were made. The Company may elect to update forward-looking statements but expressly disclaims any obligation to do so, even if its beliefs and expectations change. Actual results may differ from those expressed or implied in the forward-looking statements.
Such forward-looking statements involve and are subject to certain risks and uncertainties that may cause our actual results to differ materially from those discussed in a forward-looking statement. These include, but are not limited to the uncertainties described more fully in the Company's filings with the SEC.

CONTACT: Investor and Media Contact: Alex Wellins

The Blueshirt Group

(415) 217 - 5861

alex®blueshirtgroup.com

distributed by
Recommend :
0
React to this article
Latest news
Date Title
<1m ago PREMIER EXHIBITIONS : Announces board of director changes
<1m ago MASUPARIA GOLD : Reports Greywacke North Preliminary Drill Results
<1m ago GL EVENTS : Comfi-02-09-2014
<1m ago ESPIRITO SANTO FINANCIAL : ESFG informs on Tranquilidade
<1m ago SUNRISE REAL ESTATE : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities (form 8-K)
<1m ago Now Every Cop Can Have a Body Worn Camera; VIEVU Offers 'Straight Shooter 25', the no Cost Startup Program for Law Enforcement Agencies
<1m ago KEY DIGITAL(R) PRESENTS NEW PHANTOM SERIES(TM) 4K HDMI SWITCHERS WITH AUDIO DE-EMBEDDER : KD-HD2x1ProK and KD-HD4x1ProK
1m ago WHITESTONE REIT : Welcomes Three New Tenants to Carefree Property
2m ago HAINAN STRAIT SHIPPING : China opens South China Sea cruise route
2m ago BAYERISCHE MOTOREN WERKE : Cars for sale
Latest news
Advertisement
Hot News 
BANCO ESPIRITO SANTO : Espirito Santo debt attracts potential buyers at 2 percent of face value
CORRECT : Dixons Carphone Confirms Long Term Deal With Vodafone
OAKLEY CAPITAL INVESTMENTS : Reports Net Asset Value Fall
EXELIXIS : Announces Results from the COMET-1 Phase 3 Pivotal Trial of Cabozantinib in Men with Metastatic Castration-Resistant Prostate Cancer
COMPUWARE : to be Acquired by Thoma Bravo
Most Read News
1d ago FORMFACTOR : Raises Third Quarter Guidance Range
1d ago STUART OLSON : announces sale of Broda Construction
1d ago MEDICINOVA : to Present Data on MN-001 (tipelukast) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) During the 18th International Colloquium on Lung and Airway Fibrosis (ICLAF)
10h ago MANCHESTER UNITED : Van Gaal Speaks on Di Maria Injury
1d ago EXELIXIS : Announces Results from the COMET-1 Phase 3 Pivotal Trial of Cabozantinib in Men with Metastatic Castration-Resistant Prostate Cancer
Most recommended articles
1d agoDJZambia Copper Miners Say Crippled by Unpaid $600 Million Tax Refund-Mines Body
4d ago S&P 500 edges up to set new record; best month since Feb
12m agoDJMetro AG to Sell 9% Stake in UK's Booker Group
14m agoDJLONDON MARKETS : Weir, Tesco Climb As FTSE 100 Edges Up
19m agoDJCURRENCIES : Dollar Rises, Nears 2014 Record Against Yen
Dynamic quotes  
ON
| OFF